Aurinia Pharmaceuticals Inc. (AUPH) stock
AUPHNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 13/3058% below fair value
$15.13−0.27 (-1.75%)
Close on Nov 18, 2026Market cap $2.03BP/E 6.6Yield –
Aurinia Pharmaceuticals operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Aurinia Pharmaceuticals's operating income for the twelve months ending Sep 30, 2026 was $156.37M, up 123.4% year over year. For fiscal 2025 it was $104.91M. The highest annual figure on record is $104.91M in fiscal 2025.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $104.91M | – |
| FY2024 | Dec 31, 2024 | -$4.69M | – |
| FY2023 | Dec 31, 2023 | -$91.69M | – |
| FY2022 | Dec 31, 2022 | -$111.47M | – |
| FY2021 | Dec 31, 2021 | -$180.74M | – |
| FY2020 | Dec 31, 2020 | -$104.29M | – |
| FY2019 | Dec 31, 2019 | -$90.94M | – |
| FY2018 | Dec 31, 2018 | -$55.24M | – |
| FY2017 | Dec 31, 2017 | -$46.87M | – |
| FY2016 | Dec 31, 2016 | -$25.03M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $35.36M | +18.9% |
| Q2 FY2026 | Jun 30, 2026 | $46.34M | +130.7% |
| Q1 FY2026 | Mar 31, 2026 | $41.42M | +89.6% |
| Q4 FY2025 | Dec 31, 2025 | $33.24M | – |
| Q3 FY2025 | Sep 30, 2025 | $29.75M | +153.2% |
| Q2 FY2025 | Jun 30, 2025 | $20.08M | – |
| Q1 FY2025 | Mar 31, 2025 | $21.85M | – |
| Q4 FY2024 | Dec 31, 2024 | -$1.67M | – |
| Q3 FY2024 | Sep 30, 2024 | $11.75M | – |
| Q2 FY2024 | Jun 30, 2024 | -$1.51M | – |
| Q1 FY2024 | Mar 31, 2024 | -$13.25M | – |
| Q4 FY2023 | Dec 31, 2023 | -$29.67M | – |
| Q3 FY2023 | Sep 30, 2023 | -$16.26M | – |
| Q2 FY2023 | Jun 30, 2023 | -$16.17M | – |
| Q1 FY2023 | Mar 31, 2023 | -$29.58M | – |
| Q4 FY2022 | Dec 31, 2022 | -$28.10M | – |
| Q3 FY2022 | Sep 30, 2022 | -$9.50M | – |
| Q2 FY2022 | Jun 30, 2022 | -$35.99M | – |
| Q1 FY2022 | Mar 31, 2022 | -$37.88M | – |
| Q4 FY2021 | Dec 31, 2021 | -$32.71M | – |
| Q3 FY2021 | Sep 30, 2021 | -$50.35M | – |
| Q2 FY2021 | Jun 30, 2021 | -$47.13M | – |
| Q1 FY2021 | Mar 31, 2021 | -$50.54M | – |
| Q4 FY2020 | Dec 31, 2020 | -$8.05M | – |
| Q3 FY2020 | Sep 30, 2020 | -$42.32M | – |
| Q2 FY2020 | Jun 30, 2020 | -$26.86M | – |
| Q1 FY2020 | Mar 31, 2020 | -$27.06M | – |
| Q4 FY2019 | Dec 31, 2019 | -$34.84M | – |
| Q3 FY2019 | Sep 30, 2019 | -$24.07M | – |
| Q2 FY2019 | Jun 30, 2019 | -$17.14M | – |
| Q1 FY2019 | Mar 31, 2019 | -$14.89M | – |
See a number that looks wrong?